Bph Energy Ltd

BPH Energy (BPH)

BPH is a diversified company holding investments in resources and medical technology. BPH holds a significant interest (36%) in unlisted oil and gas exploration company Advent Energy Ltd. BPH is commercialising Australian biomedical technologies emerging from collaborative research by leading universities, medical institutes and hospitals across Australia.

Advent Energy

Advent Energy is an unlisted oil and gas exploration and production company formed in 2004 and based in Perth, Western Australia. Advent has assembled an attractive portfolio of assets both on and offshore Australia that have had an estimated $81 million spent on historic exploration.

All permits are located next to a ready market and/or excellent infrastructure, thereby maximising Advent’s ability to optimise any resources. Included in the portfolio is: Petroleum Exploration Permit 11 in the offshore Sydney Basin. This permit has been assessed to contain several multi-Tcf targets adjacent to the major population region of Sydney and excellent port and power infrastructure. Retention Licence 1 (comprising the Weaber Gas Field), in the Onshore Bonaparte Basin. Near term development opportunities of conventional resources for local markets complements the unconventional shale gas resources recently revealed. Advent has a strong board with exceptional experience. Advent’s management and board members have over 75 years combined oil industry experience.

BPHs primary investment in medtech is Cortical Dynamics’ Brain Anaesthesia Response Monitor (BARM); a device that measures a patient’s brain electrical activity (EEG) to indicate the response to drugs administered during surgery

Cortical has completed its first human clinical trial using the BAR monitor end-to-end (from electrode to monitor). The aim of study was to (a) evaluate the BAR monitor’s ability to distinguish between two doses of fentanyl, a commonly used analgesic agent, and (b) assess

the immunity of the BAR monitor to a range of mechanical and electrical artifacts known to complicate EEG measurement. In the study a total of 25 patients undergoing coronary artery graft bypass surgery were recruited in to the trial.

Significantly, the analysis concluded that CI could differentiate between the different doses of fentanyl while CS was well correlated with the Bispectral Index (BIS), a generally accepted measure of sedation. In addition this trial demonstrated the ability of the BAR monitor to operate effectively in an electrically noisy operating room environment. The trial’s findings suggest that the BAR monitor may find significant utility in the delivery of optimal and balanced surgical anaesthesia.